After-Hours Movers 01/09: (ACRS) (MRNA) (SNX) Higher; (PTLA) (SPWH) (URBN) Lower (more...)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. MSTR
5. MU
6. DFTX
7. BAUFF
8. ICE
9. KR
10. RGA

Go back to After-Hours Movers 01/09: (ACRS) (MRNA) (SNX) Higher; (PTLA) (SPWH) (URBN) Lower (more...)

Ultragenyx Pharma (RARE), Kyowa Kirin Report Submission of Supplemental Biologics License Application to FDA for Crysvita (burosumab)

January 13, 2020 8:18 AM EST

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd., (TYO: 4151) today announced that they submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) on December 18, 2019, for Crysvita® (burosumab) for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tumor-induced osteomalacia; TIO) that cannot be curatively resected or localized. The companies expect to hear back from FDA on submission acceptance and review designation in February... More

KB Home (KBH) PT Raised to $40 at RBC Capital

January 10, 2020 6:37 AM EST

RBC Capital analyst Mike Dahl raised the price target on KB Home (NYSE: KBH) to $40.00 (from $38.00) while maintaining an Outperform rating following results.

Dahl commented, "We are raising our FY20 est. to $3.88 (from $3.57) after solid 4Q orders and FY20 margin guidance,... More